DENALI THERAPEUTICS INC.24823R10506/03/2026ADVISORY VOTE ON EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER18803030FOR1880303FORBEAM THERAPEUTICS INC.07373V10506/03/2026APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER15000FOR1500FORSTOKE THERAPEUTICS, INC.86150R10706/03/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER41093250FOR4109325FORCG ONCOLOGY, INC.15694410006/04/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER315910FOR31591FORCG ONCOLOGY, INC.15694410006/04/2026TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER3159101 YEAR31591FORIONIS PHARMACEUTICALS, INC.46222210006/04/2026TO MAKE AN ADVISORY VOTE ON EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER380FOR38FORTECTONIC THERAPEUTIC, INC87897210806/08/2026ADVISORY APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER6290FOR629FORTECTONIC THERAPEUTIC, INC.87897210806/08/2026ADVISORY APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER6290FOR629FORRELAY THERAPEUTICS, INC.75943R10206/09/2026TO CONSIDER AND ACT UPON AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER10000FOR1000FORVOYAGER THERAPEUTICS, INC.92915B10606/09/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER10000FOR1000FORKORRO BIO, INC.50094610806/10/2026NON-BINDING ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER15382960FOR1538296FORPALISADE BIO, INC.69638940206/10/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.SECTION 14A SAY-ON-PAY VOTESISSUER50000FOR5000FORARCUS BIOSCIENCES, INC.03969F10906/11/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.SECTION 14A SAY-ON-PAY VOTESISSUER6750FOR675FORBIOCRYST PHARMACEUTICALS, INC.09058V10306/11/2026TO HOLD A NON-BINDING, ADVISORY VOTE REGARDING EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER10000FOR1000FORCULLINAN THERAPEUTICS, INC.23003110606/16/2026PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER89635000FOR8963500FORXENCOR, INC.98401F10506/16/2026APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THIS PROXY STATEMENT.SECTION 14A SAY-ON-PAY VOTESISSUER181940FOR18194FORAGIOS PHARMACEUTICALS, INC.00847X10406/18/2026TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER29591090FOR2959109FORARVINAS, INC.04335A10506/24/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER1000FOR100FORC4 THERAPEUTICS, INC.12529R10706/24/2026TO CAST A NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER59938010FOR5993801FORFOGHORN THERAPEUTICS INC.34417410706/24/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER26440FOR2644FORFOGHORN THERAPEUTICS INC.34417410706/24/2026TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER264401 YEAR2644FORKYMERA THERAPEUTICS, INC.50157510406/24/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER5000FOR500FORINHIBIKASE THERAPEUTICS, INC.45719W20506/26/2026TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER200000AGAINST20000AGAINSTINHIBIKASE THERAPEUTICS, INC.45719W20506/26/2026TO VOTE, ON A NON-BINDING, ADVISORY BASIS, ON THE FREQUENCY OF FUTURE NON-BINDING, ADVISORY VOTES ON COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER2000001 YEAR20000FORX4 PHARMACEUTICALS, INC.98420X20205/11/2026TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER250FOR25FORPASSAGE BIO INC70271220905/19/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT FOR THE 2026 ANNUAL MEETING.SECTION 14A SAY-ON-PAY VOTESISSUER6237040FOR623704FORPASSAGE BIO INC70271220905/19/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE FREQUENCY OF HOLDING FUTURE ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER62370401 YEAR623704FORPRECISION BIOSCIENCES, INC.74019P20705/21/2026APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS (COMMONLY REFERRED TO AS THE SAY-ON-PAY VOTE&QUOT). &QUOTSECTION 14A SAY-ON-PAY VOTESISSUER9851130FOR985113FORACADIA PHARMACEUTICALS INC.00422510805/29/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.SECTION 14A SAY-ON-PAY VOTESISSUER2000FOR200FORARROWHEAD PHARMACEUTICALS, INC.04280A10003/19/2026ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER120430FOR12043FORNEUPHORIA THERAPEUTICS INC.64136E10212/09/2025TO APPROVE (ON A NON-BINDING ADVISORY BASIS) THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DESCRIBED IN THE ACCOMPANYING MATERIALS.SECTION 14A SAY-ON-PAY VOTESISSUER19040FOR1904FORNEUPHORIA THERAPEUTICS INC.64136E10212/09/2025TO APPROVE (ON A NON-BINDING ADVISORY BASIS) THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS IN FUTURE YEARS.SECTION 14A SAY-ON-PAY VOTESISSUER190401 YEAR1904AGAINSTNEUPHORIA THERAPEUTICS INC.64136E10212/12/2025THE COMPANY'S PROPOSAL TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER19040AGAINST1904AGAINSTNEUPHORIA THERAPEUTICS INC.64136E10212/12/2025THE COMPANY'S PROPOSAL TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE FREQUENCY OF AN ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS IN FUTURE YEARS.SECTION 14A SAY-ON-PAY VOTESISSUER190401 YEAR1904AGAINSTIBIO INC45103370811/20/2025TO APPROVE, ON AN ADVISORY, NON-BINDING BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS (SAY-ON-PAY&QUOT). &QUOTSECTION 14A SAY-ON-PAY VOTESISSUER13558970FOR1355897FORIBIO INC45103370811/20/2025TO APPROVE, ON AN ADVISORY, NON-BINDING BASIS, THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES.SECTION 14A SAY-ON-PAY VOTESISSUER135589701 YEAR1355897FORTRAWS PHARMA, INC.68232V88411/21/2025TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER29780FOR2978FORTRAWS PHARMA, INC.68232V88411/21/2025TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE FREQUENCY OF HOLDING AN ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER297801 YEAR2978AGAINST